Spero Therapeutics, Inc. Common Stock
SPROStock
$1.57−31.73%52W
Market Cap$97.27M
P/E11.35x
Div yield—
Beta1.43
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-44.07%
Price vs S&P 500 (4W)-39.23%
VGM Score51.59
Market Capitalization$97.27M
P/E Ratio (Annual)11.35x
Earnings Surprise History
Q1 26-0.13est. -0.18
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SPROSpero Therapeutics, Inc. Common Stock | A | C | D | $1.57 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Spero Therapeutics is a clinical-stage biopharmaceutical company developing novel antibiotics for multi-drug-resistant bacterial infections and rare diseases. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic for MDR Gram-negative infections; SPR720 for non-tuberculous mycobacterial infections; and SPR206, an intravenous polymyxin candidate for hospital-acquired MDR Gram-negative infections.